RAD140 is a non-steroidal selective androgen receptor modulator (SARM). It is commonly described as more potent than testosterone, the main male steroid hormone, and as acting more selectively across tissues, although no trial has compared RAD 140 vs testosterone directly. In cultured cells and in rats, however, it matched testosterone at protecting nerve cells.
What each study actually compared
Study
Model
Testosterone comparator?
What it recorded
Miller et al. 2011
Binding assays; rats and monkeys
No
Androgen receptor inhibition constants of 7 and 29 nM; potent and orally bioavailable
Jayaraman et al. 2014
Cultured rat hippocampal neurons
Yes
As effective as testosterone at reducing cell death from apoptotic insults
Jayaraman et al. 2014
Gonadectomised adult male rats
No
Androgen action in peripheral tissues, largely sparing prostate
Zierau et al. 2019
Yeast androgen screen and prostate carcinoma cells
No
Androgenic activity in both, weaker in the yeast screen than in the prostate cells
LoRusso et al. 2022
22 postmenopausal women with metastatic breast cancer
No arm ran alongside
Androgen receptor engagement confirmed; liver markers the commonest adverse events
The potency side of RAD140 vs testosterone therefore rests on animal data. In those rats RAD140 acted as one of the androgens, the hormones that activate a protein inside cells known as the androgen receptor, while largely sparing prostate tissue, the androgen-dependent gland of the male reproductive tract. In the only human trial, which enrolled postmenopausal women with advanced breast cancer, liver enzymes, the blood markers of injury to liver cells, rose in most participants. Outside the trial record, RAD140 is also widely described as producing a marked fall in natural testosterone, the hormone that testosterone replacement therapy (TRT) supplies.
So whether RAD 140 is stronger than testosterone can be argued only from binding assays, from rats and from one trial in cancer patients. This article sets out that trial, the published case report and the laboratory and animal studies, and places them beside what the same literature says of testosterone therapy. It leaves aside how testosterone is prescribed or obtained, and UK law.
What RAD140 is, and how it differs from testosterone
RAD140 and testosterone are not the same molecule, although both bind the androgen receptor. Testosterone is a steroid hormone secreted by the testes; steroids are compounds built on four fused carbon rings. RAD140 is a designed compound. The paper that introduced it characterises a potent, orally bioavailable, non-steroidal selective androgen receptor modulator, one that reaches the circulation when administered orally and carries no steroid skeleton. Asking whether RAD 140 is testosterone therefore mistakes a synthetic receptor ligand for a hormone: the molecule rests on a 5-phenyloxadiazole nucleus, not on a steroid skeleton.
Testolone vs testosterone thus sets a designed ligand against an endogenous hormone, and RAD140 vs steroids and prohormones rests on the same distinction. Such a structure was sought on purpose: SARMs were developed to exert agonist effects in selected androgen-responsive tissues while lacking significant androgen action in prostate tissue, a selectivity that testosterone therapy does not offer. The breast cancer programme took that molecule, with the same RAD 140 mechanism of action, into the clinic as vosilasarm.
What is the difference between androgens and testosterone?
Androgens and testosterone differ as a class differs from its best-known member. Androgens are all the hormones and compounds that bind and activate the androgen receptor, and testosterone is one of them, alongside androstenedione, dehydroepiandrosterone and dihydrotestosterone (DHT), the potent androgen formed from testosterone in target tissues. Testosterone also serves as a precursor: some tissues convert it to dihydrotestosterone, others to oestradiol by aromatisation. RAD140 acts at the same receptor without a steroid structure of any kind.
What the human trial of RAD140 recorded
The only human study of RAD140 was a first-in-human phase 1 trial, the earliest stage of testing in humans. It enrolled 22 heavily pretreated postmenopausal women with ER+/HER2- metastatic breast cancer, that is oestrogen receptor-positive, HER2-negative disease that had spread beyond the breast. The trial administered 50 mg (n = 6), 100 mg (n = 13) and 150 mg (n = 3) once daily, the only RAD140 doses ever given in humans. The highest level tolerated without unacceptable toxicity, known as the maximum tolerated dose, was 100 mg a day. Once-daily administration sufficed because the elimination half-life, the time a blood concentration takes to halve, was 44.7 hours.
Liver markers dominated the safety record. The most frequent treatment-emergent adverse events were raised aspartate aminotransferase (AST) and raised alanine aminotransferase (ALT), enzymes that injured liver cells release; raised total bilirubin, the bile pigment the liver clears, followed, as did vomiting, dehydration and decreased appetite and weight, at the rates the chart sets out. Grade 3 or 4 events occurred in 72.7% of participants; treatment-related events affected 17 of 22, 7 of them at grade 3 and none at grade 4.
[Figure 1. Adverse events in RAD140’s phase 1 trial. Share of the 22 postmenopausal women with metastatic breast cancer who had each treatment-emergent adverse event, with doses of 50 to 150 mg pooled. Raised AST and ALT, markers of liver-cell injury, led. No testosterone or placebo arm ran alongside.]
No testosterone arm ran alongside in the RAD-140 research of the breast cancer programme, so the trial never made the comparison this article weighs. Its participants were women with advanced cancer, not healthy men, and the safety data speak for that population alone.
SHBG and PSA in the trial participants
Two blood markers showed that RAD140 was engaging the androgen receptor in those participants. Sex hormone-binding globulin (SHBG) is the plasma protein that carries testosterone in the blood; prostate-specific antigen (PSA) is a protein made mainly by prostate tissue under androgen stimulation. SHBG fell and PSA rose, in the numbers of participants the table gives, and paired tumour biopsies taken before and during exposure confirmed the engagement. Such markers establish only that RAD140 acted as an androgen in humans. They cannot show how far it suppresses endogenous testosterone in men, because the trial enrolled no men.
What is the difference between total and free testosterone?
Total and free testosterone differ in protein binding. Total testosterone is all of the hormone circulating in blood; free testosterone is the small fraction bound to no protein and able to enter tissues. The remainder circulates either tightly bound to sex hormone-binding globulin or loosely bound to albumin, and the free and albumin-bound portions together often go by the name bioavailable testosterone. The two measures can move apart, which is why they are read together: a fall in sex hormone-binding globulin, such as the one recorded in the trial, shifts total testosterone out of step with the free fraction.
How much does RAD140 suppress testosterone, in figures?
Beyond the trial data, suppression of natural testosterone by RAD140 is described as marked and as setting in within the first weeks of exposure. Some accounts outside the published studies describe a fall close to a shutdown; others describe one that is large but stops short of the suppression produced by anabolic-androgenic steroids. Reduced libido and fatigue have also been described as the levels fall, although a few descriptions record no change despite low readings. Such descriptions come largely from RAD-140 reddit accounts, which sometimes set the depth of suppression they describe against only a modest change in body composition.
No depth of suppression has been fixed in figures, because controlled human data are lacking; the mechanism, by contrast, is widely understood. Like other selective androgen receptor modulators, RAD140 is commonly described as signalling to the hypothalamus and the pituitary that androgen is plentiful, so that luteinising hormone (LH), the pituitary signal that drives testicular testosterone production, and follicle-stimulating hormone fall, and the testes secrete less. That loop is the hypothalamic-pituitary-testicular axis (HPTA), and along it testolone and testosterone levels are generally held to move in opposite directions. Because sex hormone-binding globulin falls as well, total and free testosterone readings grow harder to interpret.
Is testosterone safer than RAD140?
The clearest harm recorded for RAD140 outside the trial is drug-induced liver injury, a cholestatic case in a young man that the LiverTox class listing places within a recognised pattern, and the evidence for RAD-140 liver toxicity is set out in its own article.
Testosterone is generally held to carry the better-understood safety record of the two. It is a licensed medicine, one a regulator has assessed and approved for a named indication, and decades of clinical use have mapped its risks: a raised red blood cell count, suppressed spermatogenesis and unresolved questions about cardiovascular risk. RAD140 has passed through one small early-phase human trial, so its long-term safety in humans remains largely unknown.
The safety argument for RAD140 usually begins from the idea that it spares endogenous testosterone production, and it does not. Like other selective androgen receptor modulators, it is commonly described as lowering luteinising hormone and follicle-stimulating hormone, and endogenous testosterone with them, and the drug-induced liver injury of the case report weighs on the same side. Replacement therapy is not free of risk either; the comparison drawn as RAD 140 vs test E, the enanthate ester given in that therapy, turns on the fact that the ester’s risks are documented and monitored under medical supervision.
Although not Food and Drug Administration (FDA) approved, they are widely available online and are consumed to enhance athletic performance.
Does RAD140 help or harm erections compared with testosterone?
The effect of RAD140 on libido and erections is widely expected to be harm rather than help, because the suppression it produces lowers luteinising hormone and endogenous androgen output. That suppression, not any direct action of the molecule, is commonly described as the source of erectile dysfunction and of reduced libido, a weakened drive to sexual activity. Testosterone, by contrast, is widely understood to support erectile function where circulating levels run low, and modest improvement is generally described in hypogonadal trial participants. Testosterone is also partly converted to oestradiol and to dihydrotestosterone, whereas RAD140 is not aromatised and contributes nothing through oestradiol. No controlled human trial has measured erectile function after exposure to RAD140.
Is an over-the-counter test booster a better choice than RAD140 or testosterone?
Over-the-counter test boosters, supplements sold to raise endogenous testosterone output, have also been described as weak beside either RAD140 or testosterone. Beyond the trial data they are described as worthless, or at most as giving a slight lift, and outside the published trials a booster of proven effect is fairly often described as a possible substitute for a selective androgen receptor modulator. The descriptions name the following in place of, or as, test boosters:
Food, sleep and training, commonly placed ahead of any supplement
Tongkat ali, a plant extract sold as a supplement
Ashwagandha, a plant extract sold as a supplement
ZMA, a zinc and magnesium preparation with vitamin B6
Beyond the trial data, several such boosters taken in succession are described as making no difference, and a supplement of this kind is described as working on another scale altogether from a compound that binds the androgen receptor directly. Those descriptions name no single brand.
Can a natural test booster be used during or after RAD140?
A natural test booster is described, outside the trial record, as a means of holding hormone levels up during or after RAD140 exposure, but more widely as unable to offset suppression of the depth RAD140 produces. In descriptions beyond the trials, stronger agents are sometimes named instead, among them kisspeptin, a peptide that triggers gonadotrophin release, and clomiphene, an oestrogen receptor blocker that raises gonadotrophin output. Both belong to prescription or research pharmacology rather than to dietary supplements, so neither counts as a test booster at all.
RAD140 vs TRT: why SARMs were designed
The comparison of RAD140 vs TRT goes back to the SARM class, whose design had the limits of testosterone therapy in view. Testosterone declines with normal ageing in men, raising the risk of dysfunction in androgen-responsive tissues, yet testosterone therapy may itself raise the risk of prostate cancer or accelerate its progression. The aim in developing SARMs was therefore to retain agonist effects in other androgen-responsive tissues while lacking significant androgen action in prostate tissue.
That design intent held up in part in animals: RAD140 showed peripheral tissue-specific androgen action that largely spared prostate tissue in gonadectomised adult male rats, animals that surgery had deprived of their own androgens. The clinical premise behind the comparison has never been tested, because the only human trial of RAD140 enrolled women with metastatic breast cancer rather than men with low testosterone.
The use of testosterone therapy has the potential to increase the risks for developing prostate cancer and or accelerating its progression.
TRT is generally held to increase lean body mass, though not to the degree that anabolic-androgenic steroids do. Testosterone replacement returns the circulating hormone to the normal physiological range rather than above it, so its effect is commonly described as restoring lean body mass and muscle strength towards what is typical for a eugonadal man. Anabolic-androgenic steroids, by contrast, are widely understood to add far more fat-free mass at supraphysiological exposures, those above anything endogenous production reaches, because the androgen response rises with dose across and beyond the physiological range. That larger exposure is also linked to greater adverse effects on blood lipids, haematocrit and cardiac muscle.
Does RAD140 still suppress natural testosterone alongside TRT?
RAD140 is generally held to keep acting on the hypothalamic-pituitary-testicular axis even under replacement therapy, because it binds androgen receptors in the hypothalamus and the pituitary and lowers gonadotrophin signalling. Testosterone replacement therapy itself already suppresses endogenous testosterone production, so RAD140 is commonly described as adding to suppression already in place rather than starting fresh suppression. Recovery of that production afterwards is generally held to depend on how deeply the axis as a whole was suppressed, and for RAD140 with TRT that return is commonly described as uncertain in any case. The depth of the combined suppression, rather than either agent alone, is what the question turns on.
How long does natural testosterone take to recover after RAD140?
Natural testosterone is generally held to return gradually over weeks to months after RAD140 exposure ends, although no controlled human study has measured that recovery and there is no established timeline. That general view comes from androgen suppression more broadly: the depth of such suppression is generally held to follow the dose and the duration of exposure, because negative feedback lowers luteinising hormone and follicle-stimulating hormone, and endogenous testosterone with them. RAD140 itself is commonly described as cleared fairly quickly, while recovery of circulating hormone concentrations is held to lag behind its elimination. Slower or incomplete recovery is commonly associated with longer or heavier exposure, with older age and with pre-existing endocrine disorders.
Liver recovery in the published case took months rather than days, a course set out in the liver article, and the elimination half-life says only how long the compound stays in blood.
How strong RAD140 is in lab and animal studies
In the laboratory RAD140 bound the androgen receptor tightly and matched testosterone in one neuronal assay, though binding strength in vitro does not amount to strength in a living animal. The preclinical paper that characterised it describes a potent and orally bioavailable compound and gives its key binding figures as inhibition constants (Ki) of 7 and 29 nM, a measure on which a lower value marks tighter binding; the figures are in nanomolar (nM) units, one billionth of a mole per litre. The same work took RAD140 through preclinical models of anabolic androgen action in rats and monkeys.
Only the neuronal experiments on RAD140 neuroprotection used testosterone itself as the comparator among those preclinical models. RAD140 was as effective as testosterone in reducing cell death induced by apoptotic insults in cultured rat hippocampal neurons, nerve cells taken from the hippocampus. That protection depended on MAPK signalling, the mitogen-activated protein kinase pathway: phosphorylation of ERK rose, and the MAPK kinase inhibitor U0126 abolished the effect. Equal potency in cultured neurons says nothing about equal effect on lean body mass in humans, a comparison no study has made.
The anabolic to androgenic ratio of RAD140
The anabolic-to-androgenic ratio sets a compound’s effect on skeletal muscle against its effect on the prostate and seminal vesicles: growth of skeletal muscle and bone on one side, the response of the reproductive organs on the other. For RAD140 that comparison rests on the gonadectomised-rat work, which recorded androgen action in peripheral tissues together with largely spared prostate tissue. Those experiments report the uneven action of one compound across different tissues, known as tissue selectivity. No single figure appears in the studies this article draws on, so a RAD 140 anabolic ratio quoted as a number has no source here, and these papers give no RAD-140 anabolic androgenic ratio vs testosterone either.
Ideally, they show agonistic properties in anabolic target tissues, while inducing antagonistic or only weak agonistic effects in reproductive organs.
The in vitro bioassays did find clear androgenic activity. The androgenic effects of RAD-140 were weaker in a yeast androgen screen, a yeast-based test of androgen receptor activation, than in a reporter gene assay in prostate carcinoma cells, where receptor activation drives a measurable signal; in the prostate cells the responses appeared at far lower concentrations. SARMs as a class, meanwhile, are described as offering anabolic properties similar to those of steroids with a much-reduced androgenic profile.
Is DHT stronger than testosterone?
Dihydrotestosterone (DHT) is generally held to be the stronger androgen of the two, because it binds the androgen receptor with higher affinity than testosterone and dissociates from it more slowly. The enzyme 5-alpha reductase converts testosterone to dihydrotestosterone, and it is concentrated in prostate tissue, skin and hair follicles, where the conversion amplifies much of the androgenic effect. Skeletal muscle expresses little of that enzyme, so the greater potency of dihydrotestosterone stays largely confined to those tissues. RAD140 carries no steroid skeleton and is not a substrate for 5-alpha reductase at all.
Why do SARMs look as anabolic as testosterone on paper but not in practice?
SARMs look as anabolic as testosterone on paper because their figures come from two sources that are generally held to translate poorly to humans: receptor binding studies and the castrated-rat assay. That assay weighs the growth of a small skeletal muscle of the pelvic floor, the levator ani, against the growth of the prostate and seminal vesicles. A compound can look far more tissue-selective in that model than in an intact animal, because castration removes the animal’s own testosterone.
Beyond that model, testosterone acts through several routes at once: as a full agonist at the androgen receptor and as a precursor of dihydrotestosterone and oestradiol. SARMs, by contrast, are commonly described as acting more narrowly, often as partial agonists, and human trials of the class have accordingly found only modest increases in lean body mass.
Does RAD140 affect bone and masculine traits like testosterone does?
RAD140 affects bone and masculine traits less completely than testosterone does, on the general reading of the preclinical evidence. Testosterone is widely understood to support bone through two routes, direct action at the androgen receptor and conversion to oestradiol, a hormone held to be central to bone maintenance in males, while its masculinising effects on skin, hair follicles and the prostate are largely attributed to dihydrotestosterone. RAD140 is generally held to undergo neither conversion. In preclinical work it is commonly described as anabolic in skeletal muscle and bone, with only partial activity in the reproductive organs, and that selectivity remains unconfirmed in humans, both for bone mineral density and for secondary sex characteristics, the masculine traits that develop at puberty.
RAD140 and testosterone in anti-doping rules
SARMs have been prohibited by WADA since 2008, and RAD140 falls under that class entry, an inclusion that rests on the myoanabolic effects attributed to the class. Because routine doping control then had to find them, laboratories characterised the behaviour of the SARM RAD140 under mass spectrometry, the method that identifies a molecule from the masses of its fragments, and reported diagnostic product ions at m/z 223 and 205 under electrospray ionisation tandem mass spectrometry (ESI-MS/MS). Such compounds were already being detected in doping control samples between 2009 and 2012, despite having no clinical approval.
Testosterone is caught by another route. Its administration is flagged through the testosterone/epitestosterone ratio rather than by a foreign molecule, so samples with a suspicious ratio risk being reported as negative when no other steroid accompanies them. In that respect the two sit at opposite ends of one testing problem: a synthetic ligand is foreign to human physiology and identifiable as such, whereas the hormone is already there.
[Figure 2. How doping tests find RAD140 and testosterone. Anti-doping laboratories identify RAD140 as a foreign molecule by its mass spectrometric fragments at m/z 223 and 205. Testosterone use is inferred from the testosterone/epitestosterone ratio, which can let samples be reported falsely negative.]
Does RAD140 show up as testosterone in blood tests?
RAD140 does not read as testosterone on a routine blood test, because such a test measures the steroid itself and RAD140 is a non-steroidal molecule of a different structure. In most panels that measurement rests on an antibody-based method known as an immunoassay, which detects testosterone rather than overall androgen receptor activity. A testosterone result taken during exposure is therefore commonly described as reflecting endogenous production, and both that result and sex hormone-binding globulin are generally expected to read low. The molecule itself escapes a hormone panel; detecting RAD140 on a drug test takes targeted mass spectrometry.
What the evidence cannot yet settle
The published evidence cannot settle RAD 140 vs testosterone in humans, because no trial has set RAD140 against testosterone, alone or as testosterone replacement therapy. Its single human trial enrolled 22 postmenopausal women with metastatic breast cancer, a population that makes the safety and marker data weak evidence for healthy men, while the findings on strength and selectivity come from cells, rats and monkeys, where tissue selectivity is easier to demonstrate than in an intact human. The products sold under the name set a limit of their own, because they have been found under-dosed or mixed with other compounds: an effect attributed to RAD140 alone may not come from RAD140. The UK SARMs for sale here come with batch documentation, so a laboratory comparison at least starts from known compounds.
The effects described outside the published trials are the depth and symptoms of suppression of natural testosterone and what over-the-counter test boosters do during or after exposure; no published study among this article’s sources has measured them.
Products sold as RAD140 often depart from their labels and urine samples outside sport often hold several compounds at once, so comparisons drawn from such material compare mixtures rather than compounds; the RAD-140 for sale here is supplied for laboratory research with batch and purity documentation.
[Figure 3. RAD140’s published evidence, 2011 to 2023. The sources this article draws on, by year and model: laboratory and animal studies from 2011 to 2019, one phase 1 trial in 22 women with advanced breast cancer, and one case of liver injury. None was in healthy men or against testosterone.]
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
In the one experiment that set RAD140 directly against testosterone, what did it find?
RAD140 matched testosterone at shielding cultured rat nerve cells ✓
RAD140 added more lean mass than testosterone in castrated rats
RAD140 outperformed testosterone on strength in healthy young adults
RAD140 bound the androgen receptor more tightly than testosterone
In cultured rat hippocampal neurons RAD140 was as effective as testosterone at reducing cell death. No study has compared the two on muscle or strength.
Who were the participants in the only human trial of RAD140?
Older men with low testosterone on replacement
Postmenopausal women with advanced breast cancer ✓
Healthy young men in a resistance training study
Men with prostate cancer after surgical castration
The only human trial enrolled 22 postmenopausal women with ER+/HER2- metastatic breast cancer, and raised liver enzymes were its most common adverse events.
In the published liver injury case, when did the man's liver enzymes return to normal after RAD140 was stopped?
Within two days, as the compound cleared
Between three and twelve months later ✓
Within a week of the jaundice appearing
Only after a liver transplant
His liver enzymes normalised three to 12 months after he stopped the product, so recovery was counted in months, not in days.
What did the re-analysis of Swedish healthcare urine samples show about the samples that were positive for SARMs?
RAD140 was the single most common SARM found
SARMs appeared in women as often as in men
Over half held two or more different SARMs ✓
Most also held anabolic-androgenic steroids
SARMs were found in 4% of male samples, and more than half of those held two or more, so the material people use is often a mixture.
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
RAD 140 and TRT have never been studied together: the only human trial was in women with breast cancer, and a case report records suppressed testosterone.
RAD 140 vs LGD has never been compared in a trial: LGD-4033’s trial lowered testosterone and HDL, while RAD140’s raised liver enzymes in most participants.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
RAD140 vs testosterone: strength, suppression and TRT
By Laura Walker, PhD · Reviewed by Elizabeth Hyams
Published · Updated · 21 min read
Is RAD140 stronger than testosterone?
RAD140 is a non-steroidal selective androgen receptor modulator (SARM). It is commonly described as more potent than testosterone, the main male steroid hormone, and as acting more selectively across tissues, although no trial has compared RAD 140 vs testosterone directly. In cultured cells and in rats, however, it matched testosterone at protecting nerve cells.
What each study actually compared
The potency side of RAD140 vs testosterone therefore rests on animal data. In those rats RAD140 acted as one of the androgens, the hormones that activate a protein inside cells known as the androgen receptor, while largely sparing prostate tissue, the androgen-dependent gland of the male reproductive tract. In the only human trial, which enrolled postmenopausal women with advanced breast cancer, liver enzymes, the blood markers of injury to liver cells, rose in most participants. Outside the trial record, RAD140 is also widely described as producing a marked fall in natural testosterone, the hormone that testosterone replacement therapy (TRT) supplies.
So whether RAD 140 is stronger than testosterone can be argued only from binding assays, from rats and from one trial in cancer patients. This article sets out that trial, the published case report and the laboratory and animal studies, and places them beside what the same literature says of testosterone therapy. It leaves aside how testosterone is prescribed or obtained, and UK law.
What RAD140 is, and how it differs from testosterone
RAD140 and testosterone are not the same molecule, although both bind the androgen receptor. Testosterone is a steroid hormone secreted by the testes; steroids are compounds built on four fused carbon rings. RAD140 is a designed compound. The paper that introduced it characterises a potent, orally bioavailable, non-steroidal selective androgen receptor modulator, one that reaches the circulation when administered orally and carries no steroid skeleton. Asking whether RAD 140 is testosterone therefore mistakes a synthetic receptor ligand for a hormone: the molecule rests on a 5-phenyloxadiazole nucleus, not on a steroid skeleton.
Testolone vs testosterone thus sets a designed ligand against an endogenous hormone, and RAD140 vs steroids and prohormones rests on the same distinction. Such a structure was sought on purpose: SARMs were developed to exert agonist effects in selected androgen-responsive tissues while lacking significant androgen action in prostate tissue, a selectivity that testosterone therapy does not offer. The breast cancer programme took that molecule, with the same RAD 140 mechanism of action, into the clinic as vosilasarm.
What is the difference between androgens and testosterone?
Androgens and testosterone differ as a class differs from its best-known member. Androgens are all the hormones and compounds that bind and activate the androgen receptor, and testosterone is one of them, alongside androstenedione, dehydroepiandrosterone and dihydrotestosterone (DHT), the potent androgen formed from testosterone in target tissues. Testosterone also serves as a precursor: some tissues convert it to dihydrotestosterone, others to oestradiol by aromatisation. RAD140 acts at the same receptor without a steroid structure of any kind.
What the human trial of RAD140 recorded
The only human study of RAD140 was a first-in-human phase 1 trial, the earliest stage of testing in humans. It enrolled 22 heavily pretreated postmenopausal women with ER+/HER2- metastatic breast cancer, that is oestrogen receptor-positive, HER2-negative disease that had spread beyond the breast. The trial administered 50 mg (n = 6), 100 mg (n = 13) and 150 mg (n = 3) once daily, the only RAD140 doses ever given in humans. The highest level tolerated without unacceptable toxicity, known as the maximum tolerated dose, was 100 mg a day. Once-daily administration sufficed because the elimination half-life, the time a blood concentration takes to halve, was 44.7 hours.
Liver markers dominated the safety record. The most frequent treatment-emergent adverse events were raised aspartate aminotransferase (AST) and raised alanine aminotransferase (ALT), enzymes that injured liver cells release; raised total bilirubin, the bile pigment the liver clears, followed, as did vomiting, dehydration and decreased appetite and weight, at the rates the chart sets out. Grade 3 or 4 events occurred in 72.7% of participants; treatment-related events affected 17 of 22, 7 of them at grade 3 and none at grade 4.
No testosterone arm ran alongside in the RAD-140 research of the breast cancer programme, so the trial never made the comparison this article weighs. Its participants were women with advanced cancer, not healthy men, and the safety data speak for that population alone.
SHBG and PSA in the trial participants
Two blood markers showed that RAD140 was engaging the androgen receptor in those participants. Sex hormone-binding globulin (SHBG) is the plasma protein that carries testosterone in the blood; prostate-specific antigen (PSA) is a protein made mainly by prostate tissue under androgen stimulation. SHBG fell and PSA rose, in the numbers of participants the table gives, and paired tumour biopsies taken before and during exposure confirmed the engagement. Such markers establish only that RAD140 acted as an androgen in humans. They cannot show how far it suppresses endogenous testosterone in men, because the trial enrolled no men.
Markers of receptor engagement in the trial
What is the difference between total and free testosterone?
Total and free testosterone differ in protein binding. Total testosterone is all of the hormone circulating in blood; free testosterone is the small fraction bound to no protein and able to enter tissues. The remainder circulates either tightly bound to sex hormone-binding globulin or loosely bound to albumin, and the free and albumin-bound portions together often go by the name bioavailable testosterone. The two measures can move apart, which is why they are read together: a fall in sex hormone-binding globulin, such as the one recorded in the trial, shifts total testosterone out of step with the free fraction.
How much does RAD140 suppress testosterone, in figures?
Beyond the trial data, suppression of natural testosterone by RAD140 is described as marked and as setting in within the first weeks of exposure. Some accounts outside the published studies describe a fall close to a shutdown; others describe one that is large but stops short of the suppression produced by anabolic-androgenic steroids. Reduced libido and fatigue have also been described as the levels fall, although a few descriptions record no change despite low readings. Such descriptions come largely from RAD-140 reddit accounts, which sometimes set the depth of suppression they describe against only a modest change in body composition.
No depth of suppression has been fixed in figures, because controlled human data are lacking; the mechanism, by contrast, is widely understood. Like other selective androgen receptor modulators, RAD140 is commonly described as signalling to the hypothalamus and the pituitary that androgen is plentiful, so that luteinising hormone (LH), the pituitary signal that drives testicular testosterone production, and follicle-stimulating hormone fall, and the testes secrete less. That loop is the hypothalamic-pituitary-testicular axis (HPTA), and along it testolone and testosterone levels are generally held to move in opposite directions. Because sex hormone-binding globulin falls as well, total and free testosterone readings grow harder to interpret.
Is testosterone safer than RAD140?
The clearest harm recorded for RAD140 outside the trial is drug-induced liver injury, a cholestatic case in a young man that the LiverTox class listing places within a recognised pattern, and the evidence for RAD-140 liver toxicity is set out in its own article.
Testosterone is generally held to carry the better-understood safety record of the two. It is a licensed medicine, one a regulator has assessed and approved for a named indication, and decades of clinical use have mapped its risks: a raised red blood cell count, suppressed spermatogenesis and unresolved questions about cardiovascular risk. RAD140 has passed through one small early-phase human trial, so its long-term safety in humans remains largely unknown.
The safety argument for RAD140 usually begins from the idea that it spares endogenous testosterone production, and it does not. Like other selective androgen receptor modulators, it is commonly described as lowering luteinising hormone and follicle-stimulating hormone, and endogenous testosterone with them, and the drug-induced liver injury of the case report weighs on the same side. Replacement therapy is not free of risk either; the comparison drawn as RAD 140 vs test E, the enanthate ester given in that therapy, turns on the fact that the ester’s risks are documented and monitored under medical supervision.
Does RAD140 help or harm erections compared with testosterone?
The effect of RAD140 on libido and erections is widely expected to be harm rather than help, because the suppression it produces lowers luteinising hormone and endogenous androgen output. That suppression, not any direct action of the molecule, is commonly described as the source of erectile dysfunction and of reduced libido, a weakened drive to sexual activity. Testosterone, by contrast, is widely understood to support erectile function where circulating levels run low, and modest improvement is generally described in hypogonadal trial participants. Testosterone is also partly converted to oestradiol and to dihydrotestosterone, whereas RAD140 is not aromatised and contributes nothing through oestradiol. No controlled human trial has measured erectile function after exposure to RAD140.
Is an over-the-counter test booster a better choice than RAD140 or testosterone?
Over-the-counter test boosters, supplements sold to raise endogenous testosterone output, have also been described as weak beside either RAD140 or testosterone. Beyond the trial data they are described as worthless, or at most as giving a slight lift, and outside the published trials a booster of proven effect is fairly often described as a possible substitute for a selective androgen receptor modulator. The descriptions name the following in place of, or as, test boosters:
Beyond the trial data, several such boosters taken in succession are described as making no difference, and a supplement of this kind is described as working on another scale altogether from a compound that binds the androgen receptor directly. Those descriptions name no single brand.
Can a natural test booster be used during or after RAD140?
A natural test booster is described, outside the trial record, as a means of holding hormone levels up during or after RAD140 exposure, but more widely as unable to offset suppression of the depth RAD140 produces. In descriptions beyond the trials, stronger agents are sometimes named instead, among them kisspeptin, a peptide that triggers gonadotrophin release, and clomiphene, an oestrogen receptor blocker that raises gonadotrophin output. Both belong to prescription or research pharmacology rather than to dietary supplements, so neither counts as a test booster at all.
RAD140 vs TRT: why SARMs were designed
The comparison of RAD140 vs TRT goes back to the SARM class, whose design had the limits of testosterone therapy in view. Testosterone declines with normal ageing in men, raising the risk of dysfunction in androgen-responsive tissues, yet testosterone therapy may itself raise the risk of prostate cancer or accelerate its progression. The aim in developing SARMs was therefore to retain agonist effects in other androgen-responsive tissues while lacking significant androgen action in prostate tissue.
That design intent held up in part in animals: RAD140 showed peripheral tissue-specific androgen action that largely spared prostate tissue in gonadectomised adult male rats, animals that surgery had deprived of their own androgens. The clinical premise behind the comparison has never been tested, because the only human trial of RAD140 enrolled women with metastatic breast cancer rather than men with low testosterone.
Does TRT build muscle like steroids?
TRT is generally held to increase lean body mass, though not to the degree that anabolic-androgenic steroids do. Testosterone replacement returns the circulating hormone to the normal physiological range rather than above it, so its effect is commonly described as restoring lean body mass and muscle strength towards what is typical for a eugonadal man. Anabolic-androgenic steroids, by contrast, are widely understood to add far more fat-free mass at supraphysiological exposures, those above anything endogenous production reaches, because the androgen response rises with dose across and beyond the physiological range. That larger exposure is also linked to greater adverse effects on blood lipids, haematocrit and cardiac muscle.
Does RAD140 still suppress natural testosterone alongside TRT?
RAD140 is generally held to keep acting on the hypothalamic-pituitary-testicular axis even under replacement therapy, because it binds androgen receptors in the hypothalamus and the pituitary and lowers gonadotrophin signalling. Testosterone replacement therapy itself already suppresses endogenous testosterone production, so RAD140 is commonly described as adding to suppression already in place rather than starting fresh suppression. Recovery of that production afterwards is generally held to depend on how deeply the axis as a whole was suppressed, and for RAD140 with TRT that return is commonly described as uncertain in any case. The depth of the combined suppression, rather than either agent alone, is what the question turns on.
How long does natural testosterone take to recover after RAD140?
Natural testosterone is generally held to return gradually over weeks to months after RAD140 exposure ends, although no controlled human study has measured that recovery and there is no established timeline. That general view comes from androgen suppression more broadly: the depth of such suppression is generally held to follow the dose and the duration of exposure, because negative feedback lowers luteinising hormone and follicle-stimulating hormone, and endogenous testosterone with them. RAD140 itself is commonly described as cleared fairly quickly, while recovery of circulating hormone concentrations is held to lag behind its elimination. Slower or incomplete recovery is commonly associated with longer or heavier exposure, with older age and with pre-existing endocrine disorders.
Liver recovery in the published case took months rather than days, a course set out in the liver article, and the elimination half-life says only how long the compound stays in blood.
How strong RAD140 is in lab and animal studies
In the laboratory RAD140 bound the androgen receptor tightly and matched testosterone in one neuronal assay, though binding strength in vitro does not amount to strength in a living animal. The preclinical paper that characterised it describes a potent and orally bioavailable compound and gives its key binding figures as inhibition constants (Ki) of 7 and 29 nM, a measure on which a lower value marks tighter binding; the figures are in nanomolar (nM) units, one billionth of a mole per litre. The same work took RAD140 through preclinical models of anabolic androgen action in rats and monkeys.
Only the neuronal experiments on RAD140 neuroprotection used testosterone itself as the comparator among those preclinical models. RAD140 was as effective as testosterone in reducing cell death induced by apoptotic insults in cultured rat hippocampal neurons, nerve cells taken from the hippocampus. That protection depended on MAPK signalling, the mitogen-activated protein kinase pathway: phosphorylation of ERK rose, and the MAPK kinase inhibitor U0126 abolished the effect. Equal potency in cultured neurons says nothing about equal effect on lean body mass in humans, a comparison no study has made.
The anabolic to androgenic ratio of RAD140
The anabolic-to-androgenic ratio sets a compound’s effect on skeletal muscle against its effect on the prostate and seminal vesicles: growth of skeletal muscle and bone on one side, the response of the reproductive organs on the other. For RAD140 that comparison rests on the gonadectomised-rat work, which recorded androgen action in peripheral tissues together with largely spared prostate tissue. Those experiments report the uneven action of one compound across different tissues, known as tissue selectivity. No single figure appears in the studies this article draws on, so a RAD 140 anabolic ratio quoted as a number has no source here, and these papers give no RAD-140 anabolic androgenic ratio vs testosterone either.
The in vitro bioassays did find clear androgenic activity. The androgenic effects of RAD-140 were weaker in a yeast androgen screen, a yeast-based test of androgen receptor activation, than in a reporter gene assay in prostate carcinoma cells, where receptor activation drives a measurable signal; in the prostate cells the responses appeared at far lower concentrations. SARMs as a class, meanwhile, are described as offering anabolic properties similar to those of steroids with a much-reduced androgenic profile.
Is DHT stronger than testosterone?
Dihydrotestosterone (DHT) is generally held to be the stronger androgen of the two, because it binds the androgen receptor with higher affinity than testosterone and dissociates from it more slowly. The enzyme 5-alpha reductase converts testosterone to dihydrotestosterone, and it is concentrated in prostate tissue, skin and hair follicles, where the conversion amplifies much of the androgenic effect. Skeletal muscle expresses little of that enzyme, so the greater potency of dihydrotestosterone stays largely confined to those tissues. RAD140 carries no steroid skeleton and is not a substrate for 5-alpha reductase at all.
Why do SARMs look as anabolic as testosterone on paper but not in practice?
SARMs look as anabolic as testosterone on paper because their figures come from two sources that are generally held to translate poorly to humans: receptor binding studies and the castrated-rat assay. That assay weighs the growth of a small skeletal muscle of the pelvic floor, the levator ani, against the growth of the prostate and seminal vesicles. A compound can look far more tissue-selective in that model than in an intact animal, because castration removes the animal’s own testosterone.
Beyond that model, testosterone acts through several routes at once: as a full agonist at the androgen receptor and as a precursor of dihydrotestosterone and oestradiol. SARMs, by contrast, are commonly described as acting more narrowly, often as partial agonists, and human trials of the class have accordingly found only modest increases in lean body mass.
Does RAD140 affect bone and masculine traits like testosterone does?
RAD140 affects bone and masculine traits less completely than testosterone does, on the general reading of the preclinical evidence. Testosterone is widely understood to support bone through two routes, direct action at the androgen receptor and conversion to oestradiol, a hormone held to be central to bone maintenance in males, while its masculinising effects on skin, hair follicles and the prostate are largely attributed to dihydrotestosterone. RAD140 is generally held to undergo neither conversion. In preclinical work it is commonly described as anabolic in skeletal muscle and bone, with only partial activity in the reproductive organs, and that selectivity remains unconfirmed in humans, both for bone mineral density and for secondary sex characteristics, the masculine traits that develop at puberty.
RAD140 and testosterone in anti-doping rules
SARMs have been prohibited by WADA since 2008, and RAD140 falls under that class entry, an inclusion that rests on the myoanabolic effects attributed to the class. Because routine doping control then had to find them, laboratories characterised the behaviour of the SARM RAD140 under mass spectrometry, the method that identifies a molecule from the masses of its fragments, and reported diagnostic product ions at m/z 223 and 205 under electrospray ionisation tandem mass spectrometry (ESI-MS/MS). Such compounds were already being detected in doping control samples between 2009 and 2012, despite having no clinical approval.
Testosterone is caught by another route. Its administration is flagged through the testosterone/epitestosterone ratio rather than by a foreign molecule, so samples with a suspicious ratio risk being reported as negative when no other steroid accompanies them. In that respect the two sit at opposite ends of one testing problem: a synthetic ligand is foreign to human physiology and identifiable as such, whereas the hormone is already there.
Does RAD140 show up as testosterone in blood tests?
RAD140 does not read as testosterone on a routine blood test, because such a test measures the steroid itself and RAD140 is a non-steroidal molecule of a different structure. In most panels that measurement rests on an antibody-based method known as an immunoassay, which detects testosterone rather than overall androgen receptor activity. A testosterone result taken during exposure is therefore commonly described as reflecting endogenous production, and both that result and sex hormone-binding globulin are generally expected to read low. The molecule itself escapes a hormone panel; detecting RAD140 on a drug test takes targeted mass spectrometry.
What the evidence cannot yet settle
The published evidence cannot settle RAD 140 vs testosterone in humans, because no trial has set RAD140 against testosterone, alone or as testosterone replacement therapy. Its single human trial enrolled 22 postmenopausal women with metastatic breast cancer, a population that makes the safety and marker data weak evidence for healthy men, while the findings on strength and selectivity come from cells, rats and monkeys, where tissue selectivity is easier to demonstrate than in an intact human. The products sold under the name set a limit of their own, because they have been found under-dosed or mixed with other compounds: an effect attributed to RAD140 alone may not come from RAD140. The UK SARMs for sale here come with batch documentation, so a laboratory comparison at least starts from known compounds.
The effects described outside the published trials are the depth and symptoms of suppression of natural testosterone and what over-the-counter test boosters do during or after exposure; no published study among this article’s sources has measured them.
Products sold as RAD140 often depart from their labels and urine samples outside sport often hold several compounds at once, so comparisons drawn from such material compare mixtures rather than compounds; the RAD-140 for sale here is supplied for laboratory research with batch and purity documentation.
Check what you remember
4 questions on this article; the right answer is marked.
In cultured rat hippocampal neurons RAD140 was as effective as testosterone at reducing cell death. No study has compared the two on muscle or strength.
The only human trial enrolled 22 postmenopausal women with ER+/HER2- metastatic breast cancer, and raised liver enzymes were its most common adverse events.
His liver enzymes normalised three to 12 months after he stopped the product, so recovery was counted in months, not in days.
SARMs were found in 4% of male samples, and more than half of those held two or more, so the material people use is often a mixture.
Laura Walker, PhD · Newcastle University
Postdoctoral Research Associate
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Elizabeth Hyams · Imperial College London · Last reviewed
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Related Posts
RAD 140 and TRT: the evidence on a testosterone base
RAD 140 and TRT have never been studied together: the only human trial was in women with breast cancer, and a case report records suppressed testosterone.
Ostarine vs LGD: trial data, RAD140, MK-677 and anavar
Ostarine vs LGD has never been tested in one trial: separate placebo trials each recorded over 1 kg more lean mass, with lower testosterone and HDL.
Is RAD 140 a steroid? How it differs from Anavar and tren
Is RAD 140 a steroid: no, it is a nonsteroidal SARM that activates the androgen receptor without the four-ring skeleton of Anavar or trenbolone.
RAD 140 vs LGD: trial data, ostarine, YK-11 and MK-677
RAD 140 vs LGD has never been compared in a trial: LGD-4033’s trial lowered testosterone and HDL, while RAD140’s raised liver enzymes in most participants.